Clene Inc.
$ 6.48
6.06%
13 Apr - close price
- Market Cap 76,323,000 USD
- Current Price $ 6.48
- High / Low $ 6.69 / 6.01
- Stock P/E N/A
- Book Value -1.62
- EPS -2.65
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.64 %
- ROE -17.38 %
- 52 Week High 13.50
- 52 Week Low 2.28
About
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$30.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-11 | 2025-08-14 | 2025-05-06 | 2025-03-11 | 2024-11-05 | 2024-08-07 | 2024-05-08 | 2024-03-13 | 2023-11-07 | 2023-08-14 | 2023-05-12 |
| Reported EPS | -0.7786 | -0.6084 | -0.78 | -0.4995 | -1.3646 | -1.1074 | -1.06 | -0.09 | -0.06 | -0.02 | -0.29 | -0.15 |
| Estimated EPS | -0.42 | -0.5633 | -0.07 | -0.784 | -0.878 | -1.32 | -1.49 | -0.08 | -0.07 | -0.09 | -0.12 | -0.14 |
| Surprise | -0.3586 | -0.0451 | -0.71 | 0.2845 | -0.4866 | 0.2126 | 0.43 | -0.01 | 0.01 | 0.07 | -0.17 | -0.01 |
| Surprise Percentage | -85.381% | -8.0064% | -1014.2857% | 36.2883% | -55.4214% | 16.1061% | 28.8591% | -12.5% | 14.2857% | 77.7778% | -141.6667% | -7.1429% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.5 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLNN
2026-04-10 21:09:15
Clene Inc. has published its 2025 Annual Report to Stockholders, emphasizing its mission to develop safe and effective treatments for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS). The report highlights the company's CNM-Au8 nanotherapeutic, which is advanced towards FDA accelerated approval for ALS based on compelling clinical data, including survival benefits and biomarker reductions. Clene Inc. also outlines its strategic focus on expanding CNM-Au8's application to Multiple Sclerosis and Parkinson's disease, leveraging its proprietary clean-surfaced nanotechnology platform.
2026-04-10 20:09:15
Clene Inc. (NASDAQ: CLNN) will hold its 2026 Annual Meeting on May 21, 2026, where stockholders will vote on electing three Class III directors, ratifying Deloitte as the independent auditor, and casting an advisory vote on executive compensation. A key proposal seeks to increase the share reserve of the Amended 2020 Stock Plan by 1,000,000 shares, bringing the total to 4,220,000, to ensure continued capacity for equity awards. The company's proxy statement outlines executive compensation, including recent salary reductions as part of cost-saving initiatives, and details related-party transactions and beneficial ownership.
2026-04-08 23:39:34
The article assesses Clene Inc (CLNN.O) valuation, concluding that the stock is undervalued. With a current price of $6.32, its fair price is estimated between $94.58 and $793.21 based on relative valuation, suggesting it is undervalued by 93.32%. Key metrics like P/S ratio (1.96), P/B ratio (-4.19), and Forward FCF yield (-25.21%) are analyzed against historical averages and competitor benchmarks.
2026-04-06 21:40:15
Ugwumba Chidozie, a ten percent owner of Clene Inc. (NASDAQ:CLNN), sold 24,925 shares of common stock for $119,889 on April 2, 2026. Despite a recent stock price increase, Clene Inc. has a "WEAK" financial health rating according to InvestingPro, with analysts not expecting profitability this year. The company recently announced significant developments for its investigational ALS treatment, CNM-Au8, including a Type C meeting with the FDA and a registered direct offering of over $28 million.
2026-04-06 21:32:52
SymBiosis II, LLC, an entity linked to Clene Inc.'s ten percent owner Ugwumba Chidozie, sold 24,925 shares of CLNN common stock on April 2, 2026, at $4.81 per share. This open-market transaction, detailed in an SEC Form 4 filing, decreased the entity's indirect holdings but still leaves them with 401,891 shares. The sale is categorized as a negative impact on filing sentiment.
2026-04-05 22:40:24
This page provides a comprehensive resource for Clene (CLNN) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights how these documents offer insights into Clene's development of CNM-Au8, its financial position, and funding for its ALS, MS, and Parkinson’s disease programs. Stock Titan updates these filings in near real-time and provides AI-powered summaries to help investors understand key elements like financing terms and regulatory milestones.
